Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03086148
Other study ID # 2017-03-16
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date July 5, 2017
Est. completion date November 20, 2018

Study information

Verified date July 2020
Source Beijing Tiantan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Perioperative depression symptom (PDS) is one of the common mental comorbidity, and influences the clinical outcomes and prognosis. However, there is no rapid acting treatment to deal with it during the limited hospital stay. This study aims to determine whether ketamine could improve the depressive symptom of peirioperative patients. It will also examine the safety for administrating ketamine as an antidepressant intraoperatively. Meanwhile, it will show if ketamine could improve anxiety, postoperative pain or delirium. This trial also will bring great concerns on patients with perioperative mental health and explore the measures to improve their psycho-related prognosis.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date November 20, 2018
Est. primary completion date August 24, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Brain tumor located supratentorial area and need to receive elective craniotomy;

2. Moderate to severe depressive symptom measured by the qualified psychiatric doctors.

3. Ages between 18 and 65 years old.

4. American Society of Anesthesiologists physical status I-III

Exclusion Criteria:

1. History of epilepsy;

2. Major depression disorder patients undergoing antidepressive therapy within 2 weeks; 3 Psychiatric illness; 4 Drug abuse; 5 History of allergy to the research drug; 6 Tumor located in the Wernick area, Broca area or the frontal pole; 7 Hyperthyroidism; 8 Patients can not cooperate with investigators on psychiatric assessments; 9 Pregnant or breast-feeding woman; 10 refuse to sign inform consent.

Study Design


Related Conditions & MeSH terms

  • Depression
  • Ketamine; Depressive Symptom; Neurosurgery; Perioperative Period

Intervention

Drug:
Ketamine
Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
Normal saline
Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.

Locations

Country Name City State
China Beijing TianTan Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate =50% reduction in MADRS scores from baseline value.The MADRS is a 10-item tool, with scores ranging from 0 to 60, and determining the severity of depression. Postoperative 3 days
Secondary The remission rate The remission rate is defined as the absolute value of MADRS no more than 10. Postoperative 3 days and discharge.
Secondary Anxiety symptom The anxious symptom is defined as HADS score no less than 11. Postoperative 3 days.
Secondary Postoperative delirium Postoperative delirium will be assessed by the Confusion Assessment Method for the Intensive Care Unit Scale (CAM-ICU) at 2 hours and 1 day after surgery. Postoperative 1 day.
Secondary Severe pain The incidence of severe pain within first postoperative three days, which is defined as mean and peak numerical rating scale (NRS) are higher than 5. Postoperative 3 days.
Secondary Postoperative 30-day quality of life reported by KPS The quality of life will be evaluated by Karnofsky performance status (KPS) at postoperative 30 days. Postoperative 30 days
Secondary Psychiatric outcomes and complications Postoperative complications include psychiatric symptoms evaluated by Brief Psychiatric Rating Scale (BPRS), manic symptoms assessed through the 11-item Young Mania Rating Scale (YMRS), and dissociative symptoms measured by the Clinician Administered Dissociative States Scale (CADSS). Moreover, postoperative complications also include aphasia, epilepsy, hemorrhage. Postoperative 3 days and discharge.